- Home
- SLGL vs BEAT Comparison
SLGL vs BEAT Comparison
Compare SLGL & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- BEAT
- Stock Information
- Founded
- SLGL 1997
- BEAT 2015
- Country
- SLGL Israel
- BEAT United States
- Employees
- SLGL N/A
- BEAT N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- SLGL Health Care
- BEAT Technology
- Exchange
- SLGL Nasdaq
- BEAT Nasdaq
- Market Cap
- SLGL 69.1M
- BEAT 63.5M
- IPO Year
- SLGL 2018
- BEAT 2021
- Fundamental
- Price
- SLGL $33.66
- BEAT $1.64
- Analyst Decision
- SLGL Strong Buy
- BEAT Buy
- Analyst Count
- SLGL 1
- BEAT 1
- Target Price
- SLGL $50.00
- BEAT $8.00
- AVG Volume (30 Days)
- SLGL 11.7K
- BEAT 82.5K
- Earning Date
- SLGL 11-07-2025
- BEAT 11-13-2025
- Dividend Yield
- SLGL N/A
- BEAT N/A
- EPS Growth
- SLGL N/A
- BEAT N/A
- EPS
- SLGL N/A
- BEAT N/A
- Revenue
- SLGL $23,931,000.00
- BEAT N/A
- Revenue This Year
- SLGL N/A
- BEAT N/A
- Revenue Next Year
- SLGL N/A
- BEAT $28.23
- P/E Ratio
- SLGL N/A
- BEAT N/A
- Revenue Growth
- SLGL 264.86
- BEAT N/A
- 52 Week Low
- SLGL $4.01
- BEAT $0.91
- 52 Week High
- SLGL $52.26
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- SLGL 45.02
- BEAT 49.10
- Support Level
- SLGL $30.85
- BEAT $1.47
- Resistance Level
- SLGL $39.00
- BEAT $1.85
- Average True Range (ATR)
- SLGL 2.87
- BEAT 0.11
- MACD
- SLGL -1.25
- BEAT -0.01
- Stochastic Oscillator
- SLGL 22.17
- BEAT 44.74
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.